Intermediate DEND syndrome

Intermediate DEND syndrome (intermediate Developmental delay, Epilepsy, and Neonatal Diabetes) is a rare genetic disorder caused by activating mutations in the KCNJ11 gene (encoding the Kir6.2 subunit of the ATP-sensitive potassium channel) or, less commonly, in the ABCC8 gene (encoding the SUR1 subunit). It represents a clinical spectrum that falls between isolated permanent neonatal diabetes mellitus and the more severe classic DEND syndrome. The condition presents in the neonatal period with diabetes mellitus due to impaired insulin secretion from pancreatic beta cells, as the mutated potassium channels fail to close appropriately in response to glucose-stimulated ATP production. The syndrome affects multiple body systems. In addition to neonatal diabetes, patients typically exhibit developmental delay and/or intellectual disability of varying severity, as well as muscle weakness. Unlike classic DEND syndrome, patients with intermediate DEND syndrome generally do not have severe epilepsy, though some may experience milder seizure activity. Motor developmental milestones are often delayed, and speech and learning difficulties are common. The neurological features are attributed to the expression of ATP-sensitive potassium channels in the brain and skeletal muscle. A major advance in treatment has been the discovery that many patients with KCNJ11 or ABCC8 mutations can be successfully transferred from insulin injections to oral sulfonylurea therapy (such as glibenclamide/glyburide). Sulfonylureas work by binding to the SUR1 subunit and closing the potassium channel, thereby restoring insulin secretion. Importantly, sulfonylurea treatment has been shown to improve not only glycemic control but also neurological outcomes in some patients, including improvements in developmental abilities and muscle function. Early genetic diagnosis and prompt initiation of sulfonylurea therapy are therefore critical for optimizing outcomes.

Common questions about Intermediate DEND syndrome